The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus

Rabea Asleh, Mohammad Sheikh-Ahmad, Alexandros Briasoulis, Sudhir S. Kushwaha

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Patients with type 2 diabetes mellitus (DM) are at a substantially increased risk of heart failure (HF) and HF mortality. Despite the lack of evidence that tight glycemic control reduces the incidence of cardiovascular (CV) events, a growing body of evidence suggests that the choice of glucose-lowering agents may influence outcomes including HF. Thiazolidinediones are associated with a significant risk of HF. For metformin, sulphonylureas and insulin, little data is available to indicate the impact on HF. The glucagon-like peptide-1 (GLP-1) agonists, liraglutide and semaglutide, have been shown to reduce major CV events, but did not affect rates of hospitalization for HF. Clinical trials have demonstrated diverse effects of Dipeptidyl peptidase-4 (DPP-4) inhibitors on HF; saxagliptin showed an increased risk of HF admissions, alogliptin was associated with higher rates of new HF admissions, while sitagliptin had a neutral effect. The sodium-glucose cotransporter 2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have been recently shown to reduce the incidence of HF and cardiovascular mortality in patients with and without a history of HF. This review will summarize key findings of the impact of glucose-lowering agents on CV safety and HF-associated outcomes, present available data on the underlying mechanisms for the benefits of the SGLT2 inhibitors on HF, and discuss strategies to improve outcomes in patients with DM and high CV risk.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalHeart Failure Reviews
DOIs
StateAccepted/In press - Dec 22 2017

Fingerprint

Type 2 Diabetes Mellitus
Heart Failure
Drug Therapy
Sodium-Glucose Transport Proteins
Dipeptidyl-Peptidase IV Inhibitors
Cardiovascular Agents
Glucose
Thiazolidinediones
Glucagon-Like Peptide 1
Mortality
Metformin
Incidence
Diabetes Mellitus
Hospitalization
Clinical Trials
Insulin
Safety

Keywords

  • Diabetes mellitus
  • GLP-1 agonists
  • Glucose-lowering drugs
  • Heart failure
  • Outcome
  • SGLT2 inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. / Asleh, Rabea; Sheikh-Ahmad, Mohammad; Briasoulis, Alexandros; Kushwaha, Sudhir S.

In: Heart Failure Reviews, 22.12.2017, p. 1-15.

Research output: Contribution to journalArticle

Asleh, Rabea ; Sheikh-Ahmad, Mohammad ; Briasoulis, Alexandros ; Kushwaha, Sudhir S. / The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. In: Heart Failure Reviews. 2017 ; pp. 1-15.
@article{e131f8093ecd4caa9f32f2b094217c52,
title = "The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus",
abstract = "Patients with type 2 diabetes mellitus (DM) are at a substantially increased risk of heart failure (HF) and HF mortality. Despite the lack of evidence that tight glycemic control reduces the incidence of cardiovascular (CV) events, a growing body of evidence suggests that the choice of glucose-lowering agents may influence outcomes including HF. Thiazolidinediones are associated with a significant risk of HF. For metformin, sulphonylureas and insulin, little data is available to indicate the impact on HF. The glucagon-like peptide-1 (GLP-1) agonists, liraglutide and semaglutide, have been shown to reduce major CV events, but did not affect rates of hospitalization for HF. Clinical trials have demonstrated diverse effects of Dipeptidyl peptidase-4 (DPP-4) inhibitors on HF; saxagliptin showed an increased risk of HF admissions, alogliptin was associated with higher rates of new HF admissions, while sitagliptin had a neutral effect. The sodium-glucose cotransporter 2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have been recently shown to reduce the incidence of HF and cardiovascular mortality in patients with and without a history of HF. This review will summarize key findings of the impact of glucose-lowering agents on CV safety and HF-associated outcomes, present available data on the underlying mechanisms for the benefits of the SGLT2 inhibitors on HF, and discuss strategies to improve outcomes in patients with DM and high CV risk.",
keywords = "Diabetes mellitus, GLP-1 agonists, Glucose-lowering drugs, Heart failure, Outcome, SGLT2 inhibitors",
author = "Rabea Asleh and Mohammad Sheikh-Ahmad and Alexandros Briasoulis and Kushwaha, {Sudhir S.}",
year = "2017",
month = "12",
day = "22",
doi = "10.1007/s10741-017-9666-8",
language = "English (US)",
pages = "1--15",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus

AU - Asleh, Rabea

AU - Sheikh-Ahmad, Mohammad

AU - Briasoulis, Alexandros

AU - Kushwaha, Sudhir S.

PY - 2017/12/22

Y1 - 2017/12/22

N2 - Patients with type 2 diabetes mellitus (DM) are at a substantially increased risk of heart failure (HF) and HF mortality. Despite the lack of evidence that tight glycemic control reduces the incidence of cardiovascular (CV) events, a growing body of evidence suggests that the choice of glucose-lowering agents may influence outcomes including HF. Thiazolidinediones are associated with a significant risk of HF. For metformin, sulphonylureas and insulin, little data is available to indicate the impact on HF. The glucagon-like peptide-1 (GLP-1) agonists, liraglutide and semaglutide, have been shown to reduce major CV events, but did not affect rates of hospitalization for HF. Clinical trials have demonstrated diverse effects of Dipeptidyl peptidase-4 (DPP-4) inhibitors on HF; saxagliptin showed an increased risk of HF admissions, alogliptin was associated with higher rates of new HF admissions, while sitagliptin had a neutral effect. The sodium-glucose cotransporter 2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have been recently shown to reduce the incidence of HF and cardiovascular mortality in patients with and without a history of HF. This review will summarize key findings of the impact of glucose-lowering agents on CV safety and HF-associated outcomes, present available data on the underlying mechanisms for the benefits of the SGLT2 inhibitors on HF, and discuss strategies to improve outcomes in patients with DM and high CV risk.

AB - Patients with type 2 diabetes mellitus (DM) are at a substantially increased risk of heart failure (HF) and HF mortality. Despite the lack of evidence that tight glycemic control reduces the incidence of cardiovascular (CV) events, a growing body of evidence suggests that the choice of glucose-lowering agents may influence outcomes including HF. Thiazolidinediones are associated with a significant risk of HF. For metformin, sulphonylureas and insulin, little data is available to indicate the impact on HF. The glucagon-like peptide-1 (GLP-1) agonists, liraglutide and semaglutide, have been shown to reduce major CV events, but did not affect rates of hospitalization for HF. Clinical trials have demonstrated diverse effects of Dipeptidyl peptidase-4 (DPP-4) inhibitors on HF; saxagliptin showed an increased risk of HF admissions, alogliptin was associated with higher rates of new HF admissions, while sitagliptin had a neutral effect. The sodium-glucose cotransporter 2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have been recently shown to reduce the incidence of HF and cardiovascular mortality in patients with and without a history of HF. This review will summarize key findings of the impact of glucose-lowering agents on CV safety and HF-associated outcomes, present available data on the underlying mechanisms for the benefits of the SGLT2 inhibitors on HF, and discuss strategies to improve outcomes in patients with DM and high CV risk.

KW - Diabetes mellitus

KW - GLP-1 agonists

KW - Glucose-lowering drugs

KW - Heart failure

KW - Outcome

KW - SGLT2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85038622350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038622350&partnerID=8YFLogxK

U2 - 10.1007/s10741-017-9666-8

DO - 10.1007/s10741-017-9666-8

M3 - Article

AN - SCOPUS:85038622350

SP - 1

EP - 15

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

ER -